ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,346.99
-0.11%
Dow Jones
38,798.99
-0.22%
US Dollar vs MXN
18.4136
0.00%
Brent Oil
79.395
0.00%
Bitcoin
69,312.29
-0.03%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Centessa Pharmaceuticals PLC (CNTA)

  7. Centessa Pharmaceuticals PLC (CNTA) Noticias

CNTA Centessa Pharmaceuticals PLC

8.80
-0.12 (-1.35%)
07 Jun 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Centessa Pharmaceuticals PLC CNTA NASDAQ Certificado de Depósito
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
-0.12 -1.35% 8.80 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
8.91 8.61 9.02 8.80 8.92
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
21/5/202407:45GLOBECentessa Pharmaceuticals to Participate in Upcoming Investor..
13/5/202415:32EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/5/202415:23EDGAR2Form 8-K - Current report
13/5/202415:10GLOBECentessa Pharmaceuticals Reports Financial Results and..
09/5/202407:01EDGAR2Form ARS - Annual Report to Security Holders
09/5/202407:00EDGAR2Form DEF 14A - Other definitive proxy statements
23/4/202420:36GLOBECentessa Pharmaceuticals Announces Pricing of $100 Million..
23/4/202415:17GLOBECentessa Pharmaceuticals Announces $100 Million Proposed..
22/4/202406:00GLOBECentessa Pharmaceuticals Announces Open IND for ORX750;..
28/3/202415:28GLOBECentessa Pharmaceuticals Reports Business Highlights and..
22/2/202407:00GLOBECentessa Pharmaceuticals to Participate in TD Cowen’s 44th..
09/2/202406:12EDGAR2Form 8-K - Current report
09/2/202406:00GLOBECentessa Pharmaceuticals to Present Additional 52-Weeks of..
02/2/202416:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202416:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202416:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202416:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202416:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202415:07EDGAR2Form 144 - Report of proposed sale of securities
22/1/202407:00GLOBECentessa Pharmaceuticals to Participate in Upcoming Investor..
09/1/202406:56EDGAR2Form 8-K - Current report
02/1/202418:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202418:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202418:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202418:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202418:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/12/202307:00GLOBECentessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P...
11/12/202306:05EDGAR2Form 8-K - Current report
10/12/202311:05GLOBECentessa Pharmaceuticals Announces New Data from an..
27/11/202315:15GLOBEAnaptys Expands Immune Cell Modulator Pipeline with..
13/11/202315:22EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202315:17EDGAR2Form 8-K - Current report
13/11/202315:05GLOBECentessa Pharmaceuticals Reports Financial Results and..
02/11/202308:09GLOBECentessa Pharmaceuticals to Present Additional 52-Weeks of..
31/10/202307:00GLOBECentessa Pharmaceuticals Announces Dosing of First Subject..
30/10/202307:00GLOBECentessa Pharmaceuticals to Participate in Upcoming Investor..
25/10/202308:49EDGAR2Form 8-K - Current report
25/10/202307:00GLOBECentessa Pharmaceuticals Announces Preclinical Data..
03/10/202316:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/10/202315:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/10/202315:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/10/202315:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/10/202315:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/10/202307:00GLOBECentessa Pharmaceuticals Announces Additions to Senior..
22/9/202315:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/9/202315:02EDGAR2Form 144 - Report of proposed sale of securities
01/9/202315:31EDGAR2Form 144 - Report of proposed sale of securities
31/8/202307:00GLOBECentessa Pharmaceuticals to Participate in the Morgan..
23/8/202316:08GLOBECentessa Pharmaceuticals to Present Preclinical Data for..
14/8/202306:18EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Su Consulta Reciente

NASDAQ
CNTA
Centessa Pharmaceuticals
BIT
NSCIT1963718
EIB European Investment ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados